PF-06372865 in Subjects With Photosensitive Epilepsy

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 16, 2015

Primary Completion Date

January 10, 2017

Study Completion Date

February 7, 2017

Conditions
Reflex Epilepsy, Photosensitive
Interventions
DRUG

PF-06372865

Single dose

DRUG

Placebo

Placebo for PF-06372865 and placebo for lorazepam

DRUG

Lorazepam

2 mg single oral dose

Trial Locations (16)

10016

New York University Comprehensive Epilepsy Center, New York

19104

Clinical and Translational Research Center, Philadelphia

Hospital of the Univ of PA Pharmacy Service, Philadelphia

University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University Comprehensive Epilepsy Center, Philadelphia

Thomas Jefferson University Hospital EEG lab, Philadelphia

Thomas Jefferson University Investigational Drug Service, Philadelphia

37232

General Clinical Research Center (GCRC), Nashville

Vanderbilt University Epilepsy Clinic, Nashville

Vanderbilt University Hospital Pharmacy, Nashville

VU Department of Neurology, Nashville

63110

Barnes Jewish Hospital, St Louis

Center for Advanced Medicine, St Louis

Washington University School of Medicine, St Louis

83702

Consultants in Epilepsy & Neurology, PLLC, Boise

21287-7247

Johns Hopkins University Department of Neurology, Baltimore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02564029 - PF-06372865 in Subjects With Photosensitive Epilepsy | Biotech Hunter | Biotech Hunter